MariTide demonstrated up to ~20% weight loss at 52 weeks without a plateau in people without Type 2 diabetes. How does this level of weight reduction compare to existing obesity treatments, and what makes the absence of a plateau clinically significant?

In patients with Type 2 diabetes, MariTide achieved up to ~17% weight loss and reduced HbA1c by 2.2 percentage points. Why is this result particularly notable, and how does it address the unmet needs of this population?

The Phase 2 study reported mild, transient gastrointestinal events like nausea and vomiting that diminished with dose escalation. How does this safety profile enhance MariTide’s viability as a long-term therapy?

Beyond weight loss, MariTide significantly improved cardiometabolic markers like blood pressure and triglycerides. How important are these secondary benefits in shaping MariTide’s potential role in comprehensive obesity management?

MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate such robust weight loss. How does this convenience factor influence patient adherence and overall treatment outcomes?

Part 2 of the study is investigating further weight loss beyond 52 weeks and durability after discontinuation. What do you anticipate this data will reveal about MariTide’s potential to minimize weight rebound?

With the planned MARITIME Phase 3 program, how do you envision MariTide fitting into the current landscape of obesity treatments, particularly for patients who do not respond well to GLP-1 monotherapies?

Obesity remains a highly prevalent yet under-treated condition globally. How might MariTide’s differentiated profile—significant weight loss, cardiometabolic benefits, and patient-friendly dosing—address barriers to treatment uptake in clinical practice?